Anemia

Ensure the healthy future

    Contact Us

    Please fill in this form for additional information on treatment, procedures, price, etc.

    About Treatment

    Anemia happens when the number of healthy red blood cells in your body is too low. Red blood cells carry oxygen to all of the body’s tissues, so a low red blood cell count indicates that the amount of oxygen in your blood is lower than it should be. Many of the symptoms of anemia are caused by decreased oxygen delivery to the body’s vital tissues and organs. Anemia is measured according to the amount of hemoglobin — the protein within red blood cells that carries oxygen from the lungs to the body’s tissues. Anemia affects more than 1.6 billion people trusted sources around the world. Women and people with chronic diseases such as cancer have the highest risk of developing anemia.

    Improvements

    Improvements that can be expected after stem cell therapy:

    There are many varieties of anemia. They are all treated differently. For this reason, we give a general description of the improvements:

    The quality of life is changing. Life begins to play with new colors!

    Weaknesses in the past.

    Physical activity begins to be carried by your body calmly and confidently.

    Tachycardia is no longer a serious problem.

    Consultation from a doctor for free

    Get advice from a leading specialist and find out how stem cells will help you.

    Get free consultation

    Reviews

    Acquired aplastic anemia

    Patient M. aged 14 was admitted to the Department of Hematology of Children Specialized Clinical Hospital with hypoplastic anemia and myelodisplastic syndrome suspected. On admittance, the patient complained headache, vertigo, palpitation, dyspnea on insignificant load, bad appetite, expressed asthenia, skin paleness and hemorrhagic eruption on lateral surfaces of extremities.

    Blood count on admittance: erythrocytes 2.4×1012/l; Hb 72 g/l; color index 0.9; leukocytes 2.4×109/l; erythrocytes, 2 %; n.p., 10 %; n.s., 19 % lymphocytes 54 %; monocytes 15 %; tr., 12×109/l; ESR 15 mm/hr. To verify the diagnosis, sternal puncture was made. Myelogram (see Tables 1, 2) showed acute suppression of myeloid, erythroid growth, practical absence of megalokaryocyte growth.

    Diagnosis: acquired aplastic anemia.

    On the 5th day in the hospital, cryopreserved hematopoietic cells were injected intravenously. Total volume of cell suspension was 3 ml; cell concentration 55×106/ml; CFU-GM count 78.6×103/ml.

    On the 42nd day from the first course of treatment hematopoietic cells were injected once again. Volume of cell suspension was 4.5 ml; cell concentration 76.5×106/ml; CFU-GM count 60.8×103….

    EmCell Clinic

    Stem Cell Therapy for Fanconi Anemia

    https://pubmed.ncbi.nlm.nih.gov/28687959/

    Stem cell therapy is the administration of stem cells to a patient to treat or prevent a disease. Since stem cells possess the long-term self-renewal capacity and provide daughter cells that differentiate into the specialized cells of each tissue, stem cell therapy will theoretically improve the disease condition for the lifetime of the patient. As the most widely used stem cell therapy, bone marrow transplantation is the treatment of choice for many kinds of blood disorders, including anemias, leukemias, lymphomas, and rare immunodeficiency diseases. For the fatal genetic blood disorder Fanconi anemia, allogeneic bone marrow transplantation has remained the only curative treatment. But the recent advances in stem cell and gene therapy fields may provide promising opportunities for an alternative or even better management of Fanconi anemia. Many of these new ideas and opportunities are also useful for treating other blood diseases that affect hematopoietic stem cells, such as sickle cell anemia, severe combined immunodeficiencies, and beta-thalassemias. In this chapter, these advances along with their challenges and limitations will be thoroughly discussed.

    Human embryonic stem cell therapy for aplastic anemia

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458044/

    Human embryonic stem cell (hESC) therapy is the potential therapeutic option for the treatment of patients with aplastic anemia (AA). The study showed a remarkable improvement in the AA patient subsequent to hESC administration. No adverse events occurred in the patient. hESC therapy is safe and effective for AA patients Keywords: Aplastic anemia, human embryonic stem cells, stem cells, transplantation